Parkinson's, Dementia & Mental Health
Promising Drug Slows Down Advance of Parkinson's
Disease and Improves Symptoms
GM1 ganglioside slowed progression of disease in
patients over at least a 2-year period; once the participants went off
drug, their disease worsened
Nov. 30, 2012 - Treating Parkinson's disease
patients with the experimental drug GM1 ganglioside improved symptoms
and slowed their progression during a two and a half-year trial,
University researchers report in a new study published online
November 28 in the Journal of the Neurological Sciences.
Although the precise mechanisms of action of this
drug are still unclear, the drug may protect patients'
dopamine-producing neurons from dying and at least partially restore
their function, thereby increasing levels of dopamine, the key
neurochemical missing in the brain of Parkinson's patients.
The research team, led by senior author
Jay S. Schneider,
Ph.D., Director of the
Research Unit and Professor in the Department of Pathology,
Anatomy and Cell Biology and the Department of Neurology at Jefferson,
found that administration of GM1 ganglioside, a substance naturally
enriched in the brain that may be diminished in Parkinson's disease
brains, acted as a "neuroprotective" and a "neurorestorative" agent to
improve symptoms and over an extended period of time slow the
progression of symptoms.
What's more, once the study participants went off
the drug, their disease worsened. The study enrolled 77 subjects and
followed them over a 120-week period and also followed 17 subjects who
received current standard of care treatment for comparison.
"The drugs currently available for Parkinson's
disease are designed to treat symptoms and to improve function, but at
this time there is no drug that has been shown unequivocally to slow
disease progression," said Dr. Schneider. "Our data suggest that GM1
ganglioside has the potential to have symptomatic and disease-modifying
effects on Parkinson's disease. If this is substantiated in a larger
clinical study, GM1 could provide significant benefit for Parkinson's
Symptoms of the Parkinson's disease, which affects
over 1 million people in the United States today and is diagnosed in
60,000 adults every year, include tremors, slowness in movement,
difficulty initiating movements, difficulty walking, balance problems
and decrease in speech volume and facial expression. The motor symptoms
of Parkinson's disease result from the death of dopamine-producing
neurons in the substantia nigra, the brain region that dies in
Parkinson's disease; the cause of this cell death is unknown.
GM1 ganglioside is a chemical that is normally
found in the brain and part of the outer covering of nerve cells. It
plays important roles in neuron development and survival and modulates a
wide variety of cell activities. GM1 has been found to rescue damaged
neurons and increase dopamine levels in pre-clinical studies, and has
been suggested to have beneficial effects in other neurodegenerative
Dr. Schneider and his team made a case for the use
of GMI for Parkinson's disease beginning in the 1980s. The pathological
processes contributing to the development and progression of Parkinson's
disease are still unclear, but they appear to be multifactorial. Because
GM1 has effects on many different cellular functions, it seemed a
logical approach to try using a drug like GM1 ganglioside to modify the
pathological processes occurring in Parkinson's disease, rather than
focusing on a specific potential disease mechanism, said Dr. Schneider.
"Instead of a magic bullet, we think of it like a
magic shotgun," he said. "This study was truly a success of
The GM1 research started in mice, where Dr.
Schneider and his team found that animals with an experimentally induced
form of Parkinson's disease and administered GM1 had significantly
higher levels of dopamine in their brains and less loss of dopamine
neurons than animals that did not receive GM1.
A follow-up study in a non-human primate Parkinson
model found similar results: animals that received GM1 had higher levels
of dopamine than animals that did not and had a significant improvement
in Parkinson symptoms.
In the late 1990s, Dr. Schneider conducted a
short-term study (16 weeks) using GM1 in a small number of patients.
Improvement in symptoms was observed in patients who received GM1
compared to patients who received a non-active placebo. However, in
order to determine if there was potential for GM1 to slow the
progression of the disease, they would have to study patients over a
longer period of time—which led them to this current study.
There were three main groups of subjects in this
controlled, randomized, delayed start trial funded by the National
Institutes of Health. Patients were given a placebo for the first six
months and then GM1 for 2 years (known as the delayed start group);
patients were given GM1 from the beginning and continued on GM1 for the
duration of the study (early-start group); and a comparison group, where
patients agreed to be observed over the same time period, but did not
take the drug or a placebo—they only took the drugs prescribed by their
The delayed start study design has been suggested
to be useful for studying a drug that may have effects both on symptoms
and disease progression in Parkinson's disease.
The change over time in the Unified Parkinson's
Diseasing Rating Scale (UPDRS) motor score was the primary measure used
to assess symptoms and disease progression in patients.
At the end of the first six months of the study,
the early-start group had significant improvement in UPDRS motor scores
versus a significant worsening of scores in the delayed-start group.
Over the next two years, early start subjects maintained much of the
initial benefit of GM1 treatment, showed relatively minor symptom
progression compared to patients using standard anti-Parkinson
medications, and at the end of the study, their symptoms were still less
severe than at the start of the study over two years earlier.
Delayed start subjects also showed improvement of
symptoms after switching to GM1 use and also showed less symptom
progression over the next two years compared to the standard-of-care
patients. Both groups had significant symptom worsening over the next
one to two years after stopping use of GM1.
In short, GM1 appeared to improve symptoms and with
extended use, slow symptom progression.
"The data from this small proof-of-concept study
suggest that GM1 has the potential to have a very positive effect on the
lives of Parkinson's disease patients," said Dr. Schneider. "We've been
working on this for a long time and have some good ideas on how to move
this forward. I think it's important to continue to develop this
Financial Relief for Volkswagen Diesel Owners
You may be eligible for money damages if you owned or leased one of these VW, Porsche or Audi vehicles.
In the major scandal of 2015, Volkswagen cheated you and the world. They rigged diesel emission controls so you, nor regulators, would know how much pollution their cars were adding to our environment.
They were caught and have reserved $7.3 billion to help "make it right" with victims.
If you owned or leased one of these vehicles, contact us now.
Janicek Law attorneys are actively pursuing these cases against VW. Do Not Wait...
Janicek Law Firm, PC
(Call toll free)
VW Jetta SportWagen (2009–2014)
VW Golf (2010-2015)
VW Golf SportWagen (2015)
VW Beetle (2012–2015)
VW Passat (2012-2015)
Audi A3 (2010-2015)
VW Touareg (2009–2016)
Porsche Cayenne (2015)
Audi A6, A7, A8, Q5 Quattro (2016)